Human haemoglobin - Northfield Laboratories

Drug Profile

Human haemoglobin - Northfield Laboratories

Alternative Names: PolyHeme

Latest Information Update: 14 May 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Northfield Laboratories
  • Class Haemoglobins; Plasma expanders
  • Mechanism of Action Haemoglobin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypovolaemia

Most Recent Events

  • 08 May 2009 Northfield Laboratories lays off substantially all of its operational and staff employees
  • 01 May 2009 Northfield Laboratories receives complete response letter from the FDA for PolyHeme in Hypovolaemia
  • 31 Dec 2008 PolyHeme receives priority review status for Hypovolaemia in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top